Dr. Rivlin is the Director of the Division of Pediatric Hematology and Oncology. He has a strong interest in Sickle Cell Disease is a member of the New York Sickle Cell Advisory Committee. He has served as Principle Investigator on HRSA Sickle Cell Grants and was a member of the NIH Planning Committee for the Consensus Statement on Use of Hydroxyurea. Dr. Rivlin is the Principle Investigator of two studies, Randomized Double Blind Trial of Rivipansel in the Treatment of Vasoocclusive Crises in Hospitalized Patients with Sickle Cell Disease and An Open-Label Extension Study to Evaluate The Safety of Rivipansel in the Treatment of One or More Vasoocclusive Crises in Hospitalized Patients with Sickle Cell Disease.
Dr. Rivlin has worked in the Caribbean and Guyana on improving comprehensive sickle cell care. Dr. Rivlin is board certified in Pediatric Hematology-Oncology and he is an Assistant Professor of Pediatrics at the Albert Einstein College of Medicine.
H. H. Lehman College
Technion, Israel Institute of Technology
- Internship and Residency: Mayo Clinic Graduate School of Medicine
- Pediatric Hematology-Oncology Fellowship: Memorial Sloan-Kettering Cancer Center
- Pediatric Hematology-Oncology Chief Fellowship: Memorial Sloan-Kettering Cancer Center